Autistic Disorder Pipeline, Clinical and Non-Clinical Stage Products and FDA Approvals 2023 (Updated)
DelveInsight’s, “Autistic Disorder Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Autistic Disorder pipeline landscape. It covers the Autistic Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Autistic Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Autistic Disorder Pipeline Report
- DelveInsight’s Autistic Disorder pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Autistic Disorder treatment.
- The leading companies working in the Autistic Disorder Market include Eli Lilly and Company, Scioto Biosciences, AbbVie, Yamo Pharmaceuticals, Axial Therapeutics, Jazz Pharmaceuticals, Hoffmann-La Roche, and others.
- Promising Autistic Disorder Pipeline Therapies in the various stages of development include Aripiprazole, Memantine HCl, Aripiprazole Oral Solution, and others.
- August 2023: Otsuka Pharmaceutical Development & Commercialization Inc. announced a study of phase 3 clinical trials for Brexpiprazole. The purpose of this study is to find out about the potential benefits and safety of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.
- August 2023: MapLight Therapeutics announced a study of phase 2 clinical trials for ML-004 (IR)/(ER) tablet. ML-004-002 is a multi-center, randomized, double-blind, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD.
Request a sample and discover the recent advances in Autistic Disorder Treatment Drugs @ Autistic Disorder Pipeline Report
In the Autistic Disorder pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Autistic Disorder Overview
Autistic disorder, also known as Autism Spectrum Disorder (ASD), encompasses a spectrum of neurodevelopmental disabilities. This spectrum is characterized by repetitive patterns of behavior, interests, activities, and problems in social interactions.
Find out more about Autistic Disorder Therapeutics Assessment @ Autistic Disorder Preclinical and Discovery Stage Products
Autistic Disorder Emerging Drugs Profile
- Cariprazine: AbbVie
- L1-79: Yamo Pharmaceuticals
- AB-2004: Axial Therapeutics
Autistic Disorder Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the Autistic Disorder therapies. The Autistic Disorder companies which have their Autistic Disorder drug candidates in the most advanced stage, i.e. Phase III include, AbbVie.
Learn more about the emerging Autistic Disorder Pipeline Therapies @ Autistic Disorder Clinical Trials Assessment
Scope of the Autistic Disorder Pipeline Report
- Coverage- Global
- Autistic Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Autistic Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Autistic Disorder Companies- Eli Lilly and Company, Scioto Biosciences, AbbVie, Yamo Pharmaceuticals, Axial Therapeutics, Jazz Pharmaceuticals, Hoffmann-La Roche, and others.
- Autistic Disorder Pipeline Therapies- Aripiprazole, Memantine HCl, Aripiprazole Oral Solution, and others.
Dive deep into rich insights for new drugs for Autistic Disorder treatment, Visit @ Autistic Disorder Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Autistic Disorder: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Autistic Disorder– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Cariprazine: AbbVie
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- L1-79: Yamo Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SB-121: Scioto Biosciences
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Autistic Disorder Key Companies
- Autistic Disorder Key Products
- Autistic Disorder- Unmet Needs
- Autistic Disorder- Market Drivers and Barriers
- Autistic Disorder- Future Perspectives and Conclusion
- Autistic Disorder Analyst Views
- Autistic Disorder Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking
){kind=link}